Kisunla vs Leqembi: Side-by-Side Comparison
Quick answer: Kisunla and Leqembi are both anti-amyloid monoclonal antibody used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Kisunla | Leqembi |
|---|---|---|
| Drug class | Anti-amyloid monoclonal antibody | Anti-amyloid monoclonal antibody |
| ATC code | N07XX | N07AX |
| Primary indications | Early symptomatic Alzheimer's disease (MCI or mild dementia) | Early Alzheimer's disease, Mild cognitive impairment due to AD |
| Mechanism | Donanemab is an IgG1 monoclonal antibody that binds N-truncated pyroglutamate amyloid-β plaques, promoting their clearance | Humanized IgG1 monoclonal antibody binding soluble amyloid-beta protofibrils to reduce amyloid plaque accumulation |
| Common dose | 700 mg IV every 4 weeks for first 3 doses, then 1400 mg every 4 weeks | 10 mg/kg IV every 2 weeks |
| Detail page | Kisunla details → | Leqembi details → |
How to choose between Kisunla and Leqembi
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Anti-amyloid monoclonal antibody on iMedic · Kisunla full details · Leqembi full details
Frequently asked questions
Is Kisunla better than Leqembi?
Neither is universally 'better.' They are both anti-amyloid monoclonal antibody with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Kisunla to Leqembi?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Kisunla and Leqembi have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Kisunla and Leqembi available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.